Cantex Pharmaceuticals, Inc. announces FDA orphan drug designation has been granted to CX-01 for treatment of acute myeloid leukemia. Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of cancers and other life-threatening disorders, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to CX-01 for the treatment of acute…